Changes of HIV burden globally and in China over three decades: a secondary analysis of global HIV statistics

Abstract

Background: A more comprehensive understanding of the trends of incidence, prevalence, and mortality in human immunodeficiency virus (HIV), and their complex interrelationships, may provide important evidence for decision-making related to HIV prevention and control. The variances in these indices between different population groups, genders, and ages are critical to decipher evolving patterns of the HIV epidemic in specific populations. Methods: A secondary analysis of relevant data was conducted using data extracted from the Global Burden of Disease study of 2019. HIV/acquired immune deficiency syndrome (AIDS) incidence, prevalence, AIDS-related mortality, and mortality-to-prevalence ratio (MPR) for annual percentage change, average annual percentage change (AAPC), and corresponding 95% confidence intervals (CIs) were calculated using joinpoint regression statistical analysis. Results: The AAPC of HIV/AIDS incidence, prevalence, AIDS-related mortality rate, and MPR were –1.4 (95% CI: –1.6, –1.2), 4.1 (95% CI: 4.0, 4.3), 2.0 (95% CI: 1.7, 2.3), and –2.1 (95% CI: –2.3, –1.8) between 1990 and 2019 globally, and were 3.5 (95% CI: 2.2, 4.8), 6.9 (95% CI: 6.8, 7.0), 8.1 (95% CI: 7.1, 9.1), and 1.2 (95% CI: 0.1, 2.3) in China during the same period. In terms of differences in the preceding indicators by gender, we observed a similar pattern of trends for male and female genders both globally and in China during the entire study period. Each specific age group exhibits a distinct pattern in terms of incidence, prevalence, mortality rate, and MPR both globally and in China. Conclusions: Prevalence and mortality rates of HIV/AIDS have increased between 1990 and 2019 globally and in China. While the incidence rate and MPR have declined globally over the past three decades, these two indicators are observed to present an increasing trend in China. There is a high HIV burden among young and middle-aged adults globally; however, the elderly have a high HIV burden in China. HIV screening at older age should be scaled up, and patients with advanced HIV disease should be provided early with additional care and health resources.

Real experience of caregivers of patients with HIV/AIDS from the perspective of iceberg theory: a qualitative research

“…These measures have played a crucial role in significantly reducing new HIV infections in China, with a notable decrease from 4.8 to 2.2 per 100 000 between 2005 and 2019. 8 Furthermore, China has made significant progress towards achieving the '95-95-95' targets, which aim for 95% awareness among HIV-positive individuals, 95% treatment coverage and 95% viral suppression. Currently, the country has reached 86%, 76% and 71% of these targets, respectively, indicating substantial advancements in the HIV/AIDS response.…”

Case report: Complete response after transcatheter arterial chemoembolization combined with donafenib plus tislelizumab therapy for hepatocellular carcinoma with main trunk portal vein tumor thrombus in a patient coinfected with HIV and HBV

“…Acquired human immunodeficiency disease (AIDS), caused by HIV infection, results in partial or complete loss of immune function, rendering individuals susceptible to various opportunistic infections or tumors ( 3 , 4 ). Though the number of novel infections per year has decreased recently in China, the annual number of new infections has increased in other regions including Central Asia, Eastern Europe, and North Africa ( 5 ). Advances in medical technology have significantly prolonged the survival of patients with HIV, increasing the risk of developing malignant tumors, and an increasing proportion of patients with HIV/AIDS have been diagnosed with hepatocellular carcinoma (HCC).…”

Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment

“…In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) introduced the "90-90-90" goals, and the notable achievements in meeting these targets have propelled the adoption of a more ambitious vision to attain the "95-95-95" testing and treatment objectives by 2025 across all demographic groups, while sustaining the ongoing progress in testing and ART scale-up. [ 3 ] To attain this ambitious objective, cART plays a crucial role.…”